Cellectar Says Iopofosine I 131 Showed 87.5% Response Rate In 24-Patient Post-BTK Inhibitor Subgroup Of Phase 2b Waldenström Macroglobulinemia Trial

Loading news article.

Cellectar Says Iopofosine I 131 Showed 87.5% Response Rate In 24-Patient Post-BTK Inhibitor Subgroup Of Phase 2b Waldenström Macroglobulinemia Trial | WAPE

Cellectar Says Iopofosine I 131 Showed 87.5% Response Rate In 24-Patient Post-BTK Inhibitor Subgroup Of Phase 2b Waldenström Macroglobulinemia Trial

Article summary

Related companies

Analyzed by WAPE AI.

Comments —